combined BRCA1 and BRCA2 probability of 10%, and 20 points to a 20% probability [30] . 
RESULTS

181
Five hundred and fifty-seven women of non-Jewish ancestry underwent germline BRCA1 and 182 BRCA2 testing following a diagnosis of epithelial ovarian cancer ( with breast and/or ovarian cancer (Table 2 ).
198
The prevalence of pathogenic BRCA1/2 variants was >10% in women diagnosed with ovarian 199 cancer under the age of 60 years (21%) ( Table 4) . Also, the prevalence of pathogenic 200 BRCA1/2 variants was >10% in women diagnosed at 60 years or older with a family history 201 of breast and/or ovarian cancer (17%) or a past medical history of breast cancer (34%) ( Table   202 4). In women diagnosed with sporadic ovarian cancer at 60 years or older the prevalence of 203 pathogenic BRCA1/2 variants almost reached 10% (7/76) ( Score of ≥20 points, she is offered extended panel testing for alternative germline variants.
293
We would therefore recommend that any patient diagnosed with ovarian cancer and a family 294 history of cancer should be referred to the local genetic department irrespective of their 295 BRCA1/2 status.
296
There are some limitations with the study. Our study was biased by including mostly women In conclusion, the findings from our study suggest that if a 10% pre-test probability threshold 
